Breaking News

SynCo Bio To Manufacture Versartis Diabetes Drug

SynCo Bio Partners entered a strategic partnership with Versartis, Inc. to produce Versartis’ lead drug candidate VRS-859, a GLP-1 analog for monthly dosing to treat type 2 diabetes.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

SynCo Bio Partners entered a strategic partnership with Versartis, Inc. to produce Versartis’ lead drug candidate VRS-859, a GLP-1 analog for monthly dosing to treat type 2 diabetes. SynCo will further develop the existing production process for VRS-859 and optimize the manufacturing process to increase yields for cGMP production. “Versartis selected SynCo because of its extensive pharmaceutical manufacturing experience and its ability to deliver bulk and final product for clinical trials and...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters